Immunotherapy is an advanced form of cancer treatment that harnesses the body’s immune system to identify and destroy cancer cells. Unlike traditional treatments that directly attack tumors, immunotherapy trains the immune system to recognize cancer as a threat, offering a more targeted and personalized approach for conditions such as cervical, ovarian, and endometrial cancers.
At its core, immunotherapy enhances the immune system’s natural abilities. It helps immune cells attack cancer while sparing healthy tissue, adapt to changes in cancer behavior, and “remember” cancer cells so they can be detected and eliminated if the disease returns. It can also strengthen immune responses to improve the body’s overall ability to fight cancer.
Several types of immunotherapy are currently used or being studied. These include monoclonal antibodies and checkpoint inhibitors, which prevent cancer cells from evading immune detection; T-cell therapies, which modify a patient’s own immune cells to better target cancer; cancer vaccines, designed for prevention or treatment; and oncolytic virus therapies, which use modified viruses to destroy cancer cells.
In gynecologic cancers, immunotherapy is increasingly being incorporated into treatment plans, often alongside surgery, chemotherapy, radiation, or targeted therapies. It has shown particular use in advanced or recurrent cases of cervical, ovarian, and endometrial cancers.
For cervical cancer, approved options include checkpoint inhibitors such as pembrolizumab, which blocks proteins that allow cancer cells to hide from the immune system. Other therapies, such as bevacizumab, help slow tumor growth by limiting the formation of blood vessels that supply cancer cells. Preventive HPV vaccines also play a crucial role in reducing the risk of developing cervical cancer in the first place.
In ovarian cancer, immunotherapy is often considered for advanced or recurrent cases, especially when resistance to chemotherapy develops. Drugs like bevacizumab and checkpoint inhibitors such as dostarlimab and pembrolizumab are used to help control disease progression by targeting immune pathways and tumor blood supply.
For endometrial (uterine) cancer, immunotherapy options include checkpoint inhibitors like dostarlimab and pembrolizumab, which are approved for advanced or recurrent cases and may be used alone or in combination with other treatments.
While immunotherapy offers promising results, it can also produce side effects as the immune system becomes more active. Common reactions include fatigue, nausea, skin rashes, and flu-like symptoms. In some cases, the immune system may mistakenly attack healthy tissues, leading to inflammation in organs such as the lungs, intestines, or liver. These effects vary depending on the patient and the specific treatment used.
As research continues, immunotherapy is becoming an increasingly important part of gynecologic cancer care, offering new hope through treatments that are more precise, adaptable, and personalized than ever before.
